Mind Medicine (MindMed) Inc. (NASDAQ: MNMD), (the “Company” or “MindMed”), a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders, announced today that it will present detailed results from its phase 2b study of MM120 in Generalized Anxiety Disorder (GAD), as well as multiple presentations describing the epidemiology and growing burden of GAD at two upcoming medical conferences:
American Psychiatric Association (APA) 2024 Congress, New York, NY
Title: Rapid and Durable Response to a Single Dose of MM120 (Lysergide) in Generalized Anxiety Disorder: A Dose-Optimization Study
Format: Poster
Presenter: Dan Karlin, MD
Date: Saturday, May 4, 2024
Title: Screening Adults in the US General Population to Detect Cases of Undiagnosed Generalized Anxiety Disorder
Format: Poster
Presenter: Phong Duong, PharmD
Date: Saturday, May 4, 2024
Title: Quantifying the Burden of Undiagnosed Generalized Anxiety Disorder in the US General Adult Population
Format: Poster
Presenter: Phong Duong, PharmD
Date: Saturday, May 4, 2024
International Society for Pharmacoeconomics and Outcomes Research (ISPOR) 2024, Atlanta, GA
Title: Health-related Quality of Life Among Adults Diagnosed with Generalized Anxiety Disorder in the United States
Format: Poster
Presenter: Phong Duong, PharmD
Date: Monday, May 6, 2024
Title: Health Care Resource Use Associated with Undiagnosed and Diagnosed Generalized Anxiety Disorder Among Adults in the United States
Format: Poster
Presenter: Phong Duong, PharmD
Date: Monday, May 6, 2024
Title: Work Productivity Loss and Activity Impairment among Adults Diagnosed with Generalized Anxiety Disorder in the United States
Format: Poster
Presenter: Phong Duong, PharmD
Date: Wednesday, May 8, 2024
Posters will be available on MindMed’s Company website following the conferences.
MindMed is a clinical stage biopharmaceutical company developing novel product candidates to treat brain health disorders. Our mission is to be the global leader in the development and delivery of treatments that unlock new opportunities to improve patient outcomes. We are developing a pipeline of innovative product candidates, with and without acute perceptual effects, targeting neurotransmitter pathways that play key roles in brain health disorders. MindMed’s common shares trade on Nasdaq under the symbol MNMD.